The Modesto Bee Local Stock Index
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Roche Holding AG Basel American Depositary Shares (OP: RHHBY)
62.45 USD  +0.01 (+0.02%)
Official Closing Price  /  Updated: 8:10 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News Research
Blog posts about Roche Holding AG Basel American Depositary Shares
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
Biogen Misses On EPS, Provides Outlook
July 26, 2011
Biogen Idec (NASDAQ:BIIB) reported second-quarter earnings per share of $1.36, 2 cents below the Zacks Consensus Estimate of $1.38. Earnings increased 7.1% from the year-ago period. Excluding the... Read More
category NVS , RHHBY , ELN , and 4 more.
from DailyMarkets.com
Tamiflu Continues To Hurt Roche
July 21, 2011
Roche Holdings Ltd.’s (RHHBY) earnings came in at $1.85 per share for the first half of fiscal 2011, compared with $1.61 reported in the year-ago period. Earnings were helped by reduced research and... Read More
category RHHBY , Stocks , GSK , and 4 more.
from DailyMarkets.com
Merck’s Victrelis Wins EU Approval
July 19, 2011
Merck (NYSE:MRK) recently announced that its hepatitis C virus (HCV) drug, Victrelis (boceprevir), gained approval in the EU. The European Commission (EC) approved Victrelis for the treatment of... Read More
category RHHBY , MRK , Stocks , and 3 more.
from DailyMarkets.com
Roche To Acquire Germany’s Mtm Labs
July 19, 2011
Roche Holdings Ltd. (RHHBY) recently inked an agreement under which it will acquire Germany-based mtm laboratories AG. Following the completion of the acquisition, mtm labs will become a part of... Read More
category RHHBY , Stocks , External Research , and 2 more.
from DailyMarkets.com
Roche’s Cancer Drug Impresses
July 15, 2011
Roche Holdings Ltd. (RHHBY) recently reported positive data from a late-stage study of a combination treatment involving pertuzumab and Herceptin (trastuzumab). The CLEOPATRA study, which was conducted... Read More
category RHHBY , Stocks , GSK , and 2 more.
from DailyMarkets.com
Favorable Court Ruling For PDLI
July 12, 2011
PDL BioPharma (RHHBY). The court rejected Roche’s motion filed in November 2010 to dismiss PDL’s lawsuit due to lack of personal jurisdiction. The court also denied Roche and Genentech’s (a subsidiary... Read More
category NVS , RHHBY , Stocks , and 3 more.
from DailyMarkets.com
Novartis Presents Afinitor Data
July 11, 2011
Recently, Novartis (NYSE:NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated... Read More
category NVS , RHHBY , ONXX , and 4 more.
from DailyMarkets.com
Neutral On Optimer
July 05, 2011
We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) with a target price of $12.00 per share. We find the US Food and Drug Administration’s (FDA) approval of Optimer’s... Read More
category RHHBY , OPTR , External Research , and 9 more.
from DailyMarkets.com
(EC) Roche Holdings Gets FDA Panel View on Avastin
June 30, 2011
Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended that the agency should withdraw its approval... Read More
category Eli Lilly & Company , Oil & Gas Drilling & Exploration , EC , and 3 more.
from Stock Blog Hub
FDA Panel Gives View On Avastin
June 30, 2011
Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended that the agency should withdraw its approval... Read More
category RHHBY , Stocks , External Research , and 2 more.
from DailyMarkets.com
(AMD) Roche Holdings Gets Positive Data on Lucentis
June 29, 2011
Roche Holdings Ltd. (RHHBY) recently reported positive data from two late-stage studies (RISE and RIDE) on its eye drug, Lucentis. The studies were conducted to evaluate the safety and efficacy of the... Read More
category Semiconductor / Broad Line , NVS , Technology , and 5 more.
from Stock Blog Hub
Novartis Afinitor Backed In EU
June 29, 2011
Novartis AG (NYSE:NVS) received a boost recently when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of its drug Afinitor for the... Read More
category NVS , RHHBY , ONXX , and 4 more.
from DailyMarkets.com
(API) Roche Holdings Partners with Evotec
June 29, 2011
Roche Holdings Ltd. (RHHBY) recently announced a collaboration with Evotec AG for the development of oncology drugs. Under the agreement, Evotec will use its PhosphoScout platform to discover... Read More
category Technology , Semiconductor / Integrated Circuits , API , and 3 more.
from Stock Blog Hub
Positive Data On Roche’s Lucentis
June 29, 2011
Roche Holdings Ltd. (RHHBY) recently reported positive data from two late-stage studies (RISE and RIDE) on its eye drug, Lucentis. The studies were conducted to evaluate the safety and efficacy of the... Read More
category NVS , RHHBY , Stocks , and 2 more.
from DailyMarkets.com
Roche Partners With Evotec
June 28, 2011
Roche Holdings Ltd. (RHHBY) recently announced a collaboration with Evotec AG for the development of oncology drugs. Under the agreement, Evotec will use its PhosphoScout platform to discover... Read More
category RHHBY , Stocks , External Research , and 2 more.
from DailyMarkets.com
Positive Data On Vertex’ Incivek
June 24, 2011
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New... Read More
category RHHBY , External Research , Contributor , and 5 more.
from DailyMarkets.com
Neutral On Cell Therapeutics
June 23, 2011
We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25. Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for... Read More
category RHHBY , External Research , Contributor , and 5 more.
from DailyMarkets.com
Neutral On Alnylam
June 23, 2011
We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel... Read More
category RHHBY , MDT , External Research , and 9 more.
from DailyMarkets.com
(PFS) Roche Holdings Reports Positive Data on BCC Drug
June 22, 2011
Roche Holdings Ltd. (RHHBY) reported positive results from a mid-stage trial on vismodegib. The candidate is being evaluated for the treatment of advanced basal cell carcinoma (BCC). The phase II trial... Read More
category Provident Financial Services Inc , Financial , Savings & Loans , and 3 more.
from Stock Blog Hub
CTIC Posts Positive Pixantrone Data
June 20, 2011
Cell Therapeutics Inc. (CTIC) recently announced that data from an early stage study of its lead pipeline candidate, pixantrone, for an additional indication, was published in Cancer, an online... Read More
category RHHBY , Stocks , External Research , and 2 more.
from DailyMarkets.com
CTIC Set To Resubmit Pixantrone NDA
June 16, 2011
Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug... Read More
category RHHBY , SNY , Stocks , and 4 more.
from DailyMarkets.com
(MAA) Roche Holdings’ Skin Cancer Drug Impresses
June 12, 2011
Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the... Read More
category AZN , REIT / Residential , Sanofi/Aventis , and 7 more.
from Stock Blog Hub
Roche Skin Cancer Drug Impresses
June 09, 2011
Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the... Read More
category AZN , RHHBY , SNY , and 4 more.
from DailyMarkets.com
More Positive Data For Roche
June 08, 2011
Roche Holdings Ltd. (RHHBY) recently reported positive data from a late-stage trial (OCEANS) on Avastin (bevacizumab) at the annual meeting of the American Society of Clinical Oncology (ASCO). The... Read More
category RHHBY , Stocks , External Research , and 2 more.
from DailyMarkets.com
Positive Data On Roche’s Tarceva
June 07, 2011
Roche Holdings Ltd. (RHHBY) recently reported positive data from a late-stage trial (EURTAC) on Tarceva (erlotinib). The EURTAC trial was conducted in Western patients with a genetically distinct type... Read More
category AZN , RHHBY , SNY , and 4 more.
from DailyMarkets.com
Roche-Bristol Agree On Cancer Drug
June 03, 2011
Roche Holdings Ltd. (RHHBY) and Bristol-Myers Squibb Co. (NYSE:BMY) recently announced a collaboration for the development of a combination drug involving Roche’s vemurafenib and Bristol-Myers’... Read More
category RHHBY , Stocks , External Research , and 2 more.
from DailyMarkets.com
Positive Data On Roche’s RoActemra
June 02, 2011
Roche Holdings Ltd. (RHHBY) recently reported positive data on rheumatoid arthritis (RA) treatment RoActemra (tocilizumab; marketed as Actemra outside Europe) from a late-stage trial (ACT-RAY). The... Read More
category RHHBY , Stocks , External Research , and 3 more.
from DailyMarkets.com
Rules-Based Medicine Now With Myriad
June 02, 2011
Myriad Genetics (NASDAQ:MYGN) has completed the acquisition of Texas based Rules-Based Medicine (RBM) for $80 million in cash. RMB is expected to contribute $2 million in revenue during the fourth... Read More
category AZN , RHHBY , MYGN , and 3 more.
from DailyMarkets.com
PDLI Guides Q2 Revenues Of $128M
June 02, 2011
PDL BioPharma Inc.(NASDAQ:PDLI) recently announced that it expects to generate second-quarter 2011 revenues of $128.0 million, representing an increase of 7% over the year-ago revenues of $120.0... Read More
category RHHBY , ELN , PDLI , and 6 more.
from DailyMarkets.com
Vivus’ Qnexa Looks Promising
June 01, 2011
Vivus Inc. (NASDAQ:VVUS) recently presented multiple abstracts at the European Congress on Obesity. The presentations were related to studies (CONQUER and SEQUEL) on the company’s type II diabetes... Read More
category RHHBY , Stocks , GSK , and 3 more.
from DailyMarkets.com
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here